Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
09
11
2023
accepted:
21
02
2024
revised:
19
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
In the present study, reduced toxicity (FluBu3) and myeloablative (BuCy) conditioning were compared in patients with AML who received first allogeneic HSCT in MRD-negative CR1. The study included 124 adult patients who underwent HSCT from an HLA-matched (8/8) sibling, unrelated, or 1-locus mismatched (7/8) unrelated donor (MMUD). The median age was 45 years and intermediate cytogenetics comprised majority (71.8%). The 2-year OS, RFS, CIR and NRM for BuCy (n = 78, 62.9%) and FluBu3 (n = 46, 37.1%) groups were 78.3% and 84.5% (p = 0.358), 78.0% and 76.3% (p = 0.806), 7.7% and 21.5% (p = 0.074) and 14.3% and 2.2% (p = 0.032), respectively. At the time of data cut-off, relapse and NRM were the main causes of HSCT failure in each of the FluBu3 and BuCy arms. Among patients, 75% of relapsed FluBu3 patients had high-risk features of either poor cytogenetics or FLT3-ITD mutation compared with 16.7% of BuCy patients. The majority of NRM in the BuCy group was due to GVHD (73%), half of whom received MMUD transplantation. To conclude, the FluBu3 reduced toxicity conditioning showed comparable post-transplant OS and RFS to BuCy and was associated with significantly reduced NRM that was offset by a trend towards higher risk of relapse even in MRD-negative CR1 population.
Identifiants
pubmed: 38438648
doi: 10.1038/s41409-024-02255-w
pii: 10.1038/s41409-024-02255-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Mohty R, El Hamed R, Brissot E, Bazarbachi A, Mohty M. New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia. Haematologica. 2023;108:321–41.
pubmed: 36722403
pmcid: 9890036
doi: 10.3324/haematol.2022.280798
Bittencourt MCB, Ciurea SO. Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Biol Blood Marrow Transpl. 2020;26:e215–e221.
doi: 10.1016/j.bbmt.2020.06.007
Cho B-S, Min G-J, Park S, Park S-S, Shin S-H, Yahng S-A, et al. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. Am J Hematol. 2021;96:98–109.
pubmed: 32905642
doi: 10.1002/ajh.25993
Wang ES. Treating acute myeloid leukemia in older adults. Hematology. 2014;2014:14–20.
pubmed: 25696830
doi: 10.1182/asheducation-2014.1.14
Min G-J, Cho B-S, Park S-S, Park S, Jeon Y-W, Shin S-H, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood. 2022;139:1646–58.
pubmed: 35007323
doi: 10.1182/blood.2021013671
Park S, Min GJ, Park SS, Yahng S-A, Jeon Y-W, Shin S-H, et al. Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression. Biol Blood Marrow Transpl. 2020;26:2018–26.
doi: 10.1016/j.bbmt.2020.07.006
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135:449–52.
pubmed: 31826244
pmcid: 8212356
doi: 10.1182/blood.2019003662
Saraceni F, Scortechini I, Fiorentini A, Dubbini MV, Mancini G, Federici I, et al. Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently. Clin Hematol Int. 2021;3:153–60.
pubmed: 34938987
pmcid: 8690700
doi: 10.2991/chi.k.210731.001
Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transpl Cell Ther. 2021;27:483.e1–483.e6.
doi: 10.1016/j.jtct.2021.02.031
Park S-S, Kim H-J, Kim TY, Lee JY, Lee JH, Min GJ, et al. Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study. Blood Res. 2021;56:184–96.
pubmed: 34462406
pmcid: 8478627
doi: 10.5045/br.2021.2021107
Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44.
pubmed: 22959335
doi: 10.1016/S1470-2045(12)70349-2
Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5:e161–e169.
pubmed: 29550384
doi: 10.1016/S2352-3026(18)30022-X
Kröger N, Iacobelli S, Franke G-N, Platzbecker U, Uddin R, Hübel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35:2157–64.
pubmed: 28463633
doi: 10.1200/JCO.2016.70.7349
Gagelmann N, Kröger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021? Haematologica. 2021;106:1794–804.
pubmed: 33730842
pmcid: 8252938
doi: 10.3324/haematol.2020.268839
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Yu J, Du Y, Ahmad S, Patel RD, Varela JC, Chang C-C, et al. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study. Transpl Cell Ther. 2021;27:663.e1–663.e6.
doi: 10.1016/j.jtct.2021.04.017
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114–25.
doi: 10.1038/s41409-020-0803-y
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.
pubmed: 28380315
pmcid: 5455603
doi: 10.1200/JCO.2016.70.7091
Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, et al. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients. Transpl Cell Ther. 2021;27:774.e1–774.e12.
doi: 10.1016/j.jtct.2021.05.024
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67.
pubmed: 34724563
pmcid: 8718623
doi: 10.1182/blood.2021013626
Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet Study. J Clin Oncol. 2009;27:5195–201.
pubmed: 19752335
doi: 10.1200/JCO.2009.22.4865
Yanada M, Harada K, Shimomura Y, Arai Y, Konuma T. Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies. Front Oncol. 2022;12:1050633.
pubmed: 36505853
pmcid: 9732425
doi: 10.3389/fonc.2022.1050633
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344–53.
pubmed: 24914142
pmcid: 4102707
doi: 10.1182/blood-2014-02-514778
Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525–36.
pubmed: 26429297
doi: 10.1016/S1470-2045(15)00200-4
Liu D, Xu L, Zhang X, Wang Y, Yan C, Wang J, et al. Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. Int J Hematol. 2013;98:708–15.
pubmed: 24242024
doi: 10.1007/s12185-013-1460-3
Lee J-H, Joo Y-D, Kim H, Ryoo HM, Kim MK, Lee G-W, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31:701–9.
pubmed: 23129746
doi: 10.1200/JCO.2011.40.2362
Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, et al. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. Cancer. 2015;121:562–9.
pubmed: 25283774
doi: 10.1002/cncr.29087
Giebel S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, Byrne JL, Fegueux N, et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as ‘reduced-toxicity conditioning’ for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2021;56:481–91.
doi: 10.1038/s41409-020-01050-7
Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322–8.
pubmed: 16307018
doi: 10.1038/sj.leu.2404037
Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen–a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:3549–56.
pubmed: 23980086
doi: 10.1200/JCO.2013.48.8114
Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863–70.
pubmed: 24065243
pmcid: 3854108
doi: 10.1182/blood-2013-07-514448
Wiebe VJ, Smith BR, DeGregorio MW, Rappeport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol. 1992;13:241–70.
pubmed: 1476655
doi: 10.1016/1040-8428(92)90092-5
Peters C, Dalle J-H, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021;39:295–307.
pubmed: 33332189
doi: 10.1200/JCO.20.02529
Storb R, Georges GE, Gooley TA. Total Body Irradiation-Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transpl. 2019;25:e356–e362.
doi: 10.1016/j.bbmt.2019.08.005
Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, et al. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32:1787–94.
pubmed: 29950692
doi: 10.1038/s41375-018-0185-y
Dekker SE, Rea D, Cayuela J-M, Arnhardt I, Leonard J, Heuser M. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2023;43:e390010.
pubmed: 37311155
doi: 10.1200/EDBK_390010
Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134:935–45.
pubmed: 31395600
doi: 10.1182/blood.2018886960
Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, et al. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021;5:1110–21.
pubmed: 33616652
pmcid: 7903238
doi: 10.1182/bloodadvances.2020003855
Zhang C, Gu R, Zhou C, Li Y, Liu Y, Wei S, et al. Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML). Blood. 2022;140:2030–2.
doi: 10.1182/blood-2022-162459
Cho B-S, Min G-J, Park S-S, Park S, Jeon Y-W, Shin S-H, et al. Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11. Bone Marrow Transpl. 2021;56:2682–9.
doi: 10.1038/s41409-021-01384-w
Cho B-S, Min G-J, Park S-S, Park S, Jeon Y-W, Shin S-H, et al. Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1. Cancers. 2021;13:336.
pubmed: 33477584
pmcid: 7831332
doi: 10.3390/cancers13020336
Kim T-Y, Park S, Kwag D, Lee J-H, Lee J, Min G-J, et al. Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification. Cancers. 2022;14:3199.
pubmed: 35804971
pmcid: 9265052
doi: 10.3390/cancers14133199
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, et al. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica. 2023;108:2794.
pubmed: 37021540
pmcid: 10542837
doi: 10.3324/haematol.2022.282639
Ahn J-S, Kim H-J. FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022;57:32–36.
pubmed: 35483923
pmcid: 9057665
doi: 10.5045/br.2022.2022017
Llewellyn-Bennett R, Bowman L, Bulbulia R. Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol. Syst Rev. 2016;5:214.
pubmed: 27978859
pmcid: 5159967
doi: 10.1186/s13643-016-0393-3